Nucala: The power to choose

Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older.¹

Don't let patient concerns about administration hold them back.

Nucala (mepolizumab) lyophilised powder Nucala (mepolizumab) lyophilised powder

The recommended dose of Nucala is 100mg SC once every 4 weeks in adults and adolescents 12 years and older, available in pre-filled pen, pre-filled syringe or lyophilised powder. The licensed dose of Nucala in children aged 6-11 years is 40mg SC regardless of weight, and is available in lyophilised powder.¹ The pre-filled formulations are not indicated in 6-11 year olds.¹

Nucala is for subcutaneous injection only and should be administered by a healthcare professional. Nucala may be self-administered by the patient or administered by a caregiver if their healthcare professional determines that it is appropriate, and the patient or caregiver are trained in injection techniques.

**Combined primary endpoint analysis of a 12 week, open-label study that assessed the correct use of Nucala pre-filled pen in patients with SEA following training on proper pen technique at baseline. The primary endpoint of the study was the proportion of patients who were able to successfully self-administer their observed third dose in-clinic at Week 8 and was determined using a checklist of steps based on instructions for use and visual inspection of the pen (155 of 157 attempted injections). Ease of use was measured through a patient questionnaire at the end of the study using a 5-point scale (not at, a little, moderately, very, and extremely). Of the patients who successfully self-administered at primary end-point (n= 155), 151 patients completed the questionnaire.²

Dosing and Administration¹

  Patients aged 6 to 11 years Patients aged ≥12 years
Form

Lyophilised powder for
reconstitution

Pre-filled pen
Pre-filled syringe
Lyophilised powder

Administration

40 mg subcutaneously
every 4 weeks

100 mg subcutaneously
every 4 weeks

Injection site

Healthcare professional:
adomen, thigh or upper arm

Self-administration: abdomen
or thigh
Caregiver: abdomen, thigh or
upper arm

Explore efficacy data

Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older¹

Nucala is generally well tolerated. In clinical trials, Nucala had a similar incidence of adverse events vs. placebo with the exception of injection site reactions (8% vs. 3%), which occurred mainly within the first 3 injections¹

The recommended dose of Nucala is 100mg SC once every 4 weeks in adults and adolescents 12 years and older, available in a pre-filled pen, pre-filled syringe or lyophilised powder. The licensed dose of Nucala in children aged 6-11 years is 40mg SC regardless of weight and available in lyophilised powder.¹

References

  1. Nucala SmPC, 2020.
  2. Bernstein D et al. J Asthma 2019; 28:1–12. doi: 10 .1080 /02770903 .2019 .1630641 [Epub ahead of print].

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441

© 2020 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies.

PM-GB-MPL-WCNT-200026 | November 2020